Article: P2.14 Cost-utility of granulocyte-colony stimulating factors (G-CSFS) for primary prophylaxis (PP) of chemotherapy induced febrile neutropenia (FN) in non-Hodgkin’s lymphoma patients (NHL) in Belgium

€3.03